MX2016016531A - Metodos y composiciones para el tratamiento de las ulceras. - Google Patents

Metodos y composiciones para el tratamiento de las ulceras.

Info

Publication number
MX2016016531A
MX2016016531A MX2016016531A MX2016016531A MX2016016531A MX 2016016531 A MX2016016531 A MX 2016016531A MX 2016016531 A MX2016016531 A MX 2016016531A MX 2016016531 A MX2016016531 A MX 2016016531A MX 2016016531 A MX2016016531 A MX 2016016531A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating ulcers
ulcers
anemia
Prior art date
Application number
MX2016016531A
Other languages
English (en)
Spanish (es)
Inventor
M Attie Kenneth
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MX2016016531A publication Critical patent/MX2016016531A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2016016531A 2014-06-13 2015-06-12 Metodos y composiciones para el tratamiento de las ulceras. MX2016016531A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462012109P 2014-06-13 2014-06-13
US201462045808P 2014-09-04 2014-09-04
PCT/US2015/035706 WO2015192111A1 (en) 2014-06-13 2015-06-12 Methods and compositions for treating ulcers

Publications (1)

Publication Number Publication Date
MX2016016531A true MX2016016531A (es) 2017-04-25

Family

ID=54834477

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016016531A MX2016016531A (es) 2014-06-13 2015-06-12 Metodos y composiciones para el tratamiento de las ulceras.
MX2021010528A MX2021010528A (es) 2014-06-13 2016-12-13 Metodos y composiciones para el tratamiento de las ulceras.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010528A MX2021010528A (es) 2014-06-13 2016-12-13 Metodos y composiciones para el tratamiento de las ulceras.

Country Status (12)

Country Link
US (4) US9850298B2 (enExample)
EP (1) EP3154566B1 (enExample)
JP (2) JP6669673B2 (enExample)
CN (2) CN107135646B (enExample)
AP (1) AP2017009674A0 (enExample)
AU (2) AU2015274277B2 (enExample)
BR (2) BR112016029226A2 (enExample)
CA (1) CA2951926C (enExample)
MA (1) MA40008A (enExample)
MX (2) MX2016016531A (enExample)
TN (1) TN2016000553A1 (enExample)
WO (1) WO2015192111A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3494986T3 (pl) 2008-08-14 2020-11-16 Acceleron Pharma Inc. Pułapki GDF
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
TN2016000553A1 (en) * 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP4233889A3 (en) 2014-12-03 2023-10-11 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
US10913782B2 (en) 2015-04-22 2021-02-09 Biogen Ma Inc. Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases
US10548976B2 (en) 2015-05-20 2020-02-04 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type II receptor ligand traps
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
LT3496739T (lt) 2016-07-15 2021-05-25 Acceleron Pharma Inc. Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti
SI3490582T1 (sl) * 2016-07-27 2024-09-30 Acceleron Pharma Inc. Sestavki za uporabo proti zdravljenju mielofibroze
US11267865B2 (en) * 2016-10-05 2022-03-08 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
EP3522912A4 (en) 2016-10-05 2020-10-14 Acceleron Pharma Inc. HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
US11013785B2 (en) 2016-11-10 2021-05-25 Keros Therapeutics, Inc. Activin receptor type IIA variants and methods of use thereof
SI3638243T1 (sl) 2017-06-14 2025-03-31 Celgene Corporation Postopki Zdravljenja Mielofibroze In Anemije, Povezane Z Mieloproliferativno Neoplazmo
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
EP4428147A3 (en) 2017-11-09 2024-10-30 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
AU2019206634B2 (en) 2018-01-12 2024-06-27 Keros Therapeutics, Inc. Activin receptor type IIB variants and methods of use thereof
SG11202009551SA (en) * 2018-03-27 2020-10-29 Tautona Group Ip Holding Company L L C Topical and transdermal delivery of an iron chelator to prevent and treat chronic wounds
CA3098679A1 (en) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH0637520B2 (ja) 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
CA2084987C (en) 1990-06-11 2007-02-13 Larry Gold Nucleic acid ligands
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992004913A1 (en) 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
EP0542971A1 (en) 1991-05-10 1993-05-26 The Salk Institute For Biological Studies CLONING AND RECOMBINANT PRODUCTION OF RECEPTOR(S) OF THE ACTIVIN/TGF-$g(b) SUPERFAMILY
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
DE69228118T2 (de) 1991-06-25 1999-08-19 Genetics Institute Bmp-9 zusammensetzungen
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
US5808007A (en) 1993-01-12 1998-09-15 The Johns Hopkins University School Of Medicine Growth differentiation factor-3
DE69433742T2 (de) 1993-05-12 2005-07-07 Genetics Institute, LLC, Cambridge Bmp-10 zusammensetzungen
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
CA2174098C (en) 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
EP0771873A3 (en) 1995-10-27 1998-03-04 Takeda Chemical Industries, Ltd. Neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US20050244867A1 (en) 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
JP2001503266A (ja) 1996-10-25 2001-03-13 ジー．ディー．サール アンド カンパニー 環状に並べ替えたエリスロポイエチン受容体アゴニスト
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6011577A (en) 1997-06-30 2000-01-04 Polaroid Corporation Modular optical print head assembly
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
WO1999010364A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
IL135221A0 (en) 1997-10-03 2001-05-20 Chugai Pharmaceutical Co Ltd Natural humanized antibody and methods for the preparation thereof
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
CN1317967A (zh) 1998-09-17 2001-10-17 伊莱利利公司 蛋白质制剂
EP1116792B1 (en) 1998-09-22 2007-01-24 Long Yu New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP2002533726A (ja) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド 結合のための小有機分子リガンドの同定
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2359242C (en) 1999-01-21 2009-12-08 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP1174149A1 (en) 1999-04-19 2002-01-23 Kyowa Hakko Kogyo Co., Ltd. Proliferation inhibitor for androgen-independent tumor
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
DE60042021D1 (de) 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
BR0015506A (pt) 1999-11-12 2002-07-23 Maxygen Holdings Ltd Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CN1250288C (zh) 1999-12-15 2006-04-12 研究发展基金会 作为抑制素受体的β聚糖及其用途
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
MXPA02011303A (es) 2000-05-15 2003-04-25 Hoffmann La Roche Nueva composicion farmaceutica.
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
EP1303605A2 (en) 2000-07-19 2003-04-23 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides, and uses thereof
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2429473C (en) 2000-11-20 2011-02-15 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
WO2002043759A2 (en) 2000-12-01 2002-06-06 Wyeth Method and composition for modulating bone growth
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US20040132675A1 (en) 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US20040121008A1 (en) 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
ATE446771T1 (de) 2001-05-24 2009-11-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
CA2448253A1 (en) 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
JP3888998B2 (ja) 2001-07-17 2007-03-07 帝人株式会社 ＰＰＡＲδ活性化作用を測定することを特徴とする物質の選択方法及び薬剤
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
EP1463823B1 (en) 2001-12-06 2013-03-06 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
US20030224397A1 (en) 2002-02-11 2003-12-04 Genentech, Inc. Antibody variants with faster antigen association rates
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
US8053552B2 (en) 2002-04-18 2011-11-08 Mtm Laboratories, Ag Neopeptides and methods useful for detection and treatment of cancer
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20050271637A1 (en) 2002-08-16 2005-12-08 Bodine Peter Van N BMP-2 estrogen responsive element and methods of using the same
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
WO2004069237A1 (en) 2003-02-07 2004-08-19 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
US20040197828A1 (en) 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
US20070184052A1 (en) 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005009460A2 (en) 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2005025601A1 (en) 2003-09-15 2005-03-24 Monash University Follistatin isoforms and uses thereof
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
PL1706428T3 (pl) 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
AU2005229072A1 (en) 2004-03-26 2005-10-13 Acceleron Pharma Inc. BMP-3 propeptides and related methods
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
AU2005230854A1 (en) 2004-03-31 2005-10-20 Xencor, Inc BMP-7 variants with improved properties
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
US7465706B2 (en) 2004-06-24 2008-12-16 Acceleron Pharma Inc. GDF3 propeptides and related methods
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US8617815B2 (en) 2004-08-05 2013-12-31 The Regents Of The University Of California Molecules with effects on cellular development and function
JP2008509927A (ja) 2004-08-12 2008-04-03 ワイス Ｇｄｆ−８阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
WO2006039400A2 (en) 2004-09-29 2006-04-13 Mount Sinai School Of Medicine Of New York University Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP2954903A1 (en) 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
EP1884235A1 (en) 2005-04-26 2008-02-06 Ajinomoto Co., Inc. Myeloerythroid progenitor differentiation inducer
MY169746A (en) 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
PT1931697E (pt) 2005-09-28 2010-12-06 Zymogenetics Inc Antagonistas de il-17a e il-17f e processos para a sua utilização
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
ES2839549T3 (es) 2005-11-23 2021-07-05 Acceleron Pharma Inc Antagonistas de activina-ActRIIa de utilización en la estimulación del crecimiento óseo
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009518422A (ja) 2005-12-06 2009-05-07 アムジェン インコーポレイテッド ミオスタチン・アンタゴニストの使用
CA2632936A1 (en) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP1962835A2 (en) 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
EP1973909A2 (en) 2005-12-22 2008-10-01 Biogen Idec MA Inc. Transforming growth factor modulators
JP4822562B2 (ja) 2006-01-20 2011-11-24 ベックマン コールター， インコーポレイテッド 低ヘモグロビン濃度細胞百分率および鉄欠乏の検出における使用方法
JP2009531280A (ja) 2006-01-25 2009-09-03 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
AU2007220868B2 (en) 2006-02-28 2011-06-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007120767A2 (en) 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP2023913A2 (en) 2006-05-09 2009-02-18 Colorado State University Research Foundation Methods for treating blood disorders
AR060871A1 (es) 2006-05-09 2008-07-16 Genentech Inc Union de polipeptidos con supercontigos optimizados
JP5335674B2 (ja) 2006-07-21 2013-11-06 ライン ラボラトリーズ 酢酸カルシウムの液体組成物
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
US20100003190A1 (en) 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
ME02335B (me) * 2006-12-18 2013-04-30 Acceleron Pharma Inc Activin-actrii antagonisti i upotreba za liječenje anemije
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
BRPI0807506B1 (pt) 2007-02-09 2022-02-15 Acceleron Pharma, Inc Uso de uma proteína de fusão actriia-fc para a fabricação de um medicamento para tratar ou previnir mieloma múltiplo
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
MX2009012934A (es) 2007-06-01 2009-12-15 Wyeth Corp Metodos y composiciones para modular la actividad de bmp-10.
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
SI2170396T1 (sl) 2007-08-03 2017-04-26 Summit (Oxford) Limited Kombinacije zdravil za zdravljenje duchennove mišične distrofije
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (en) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
WO2009035629A1 (en) 2007-09-13 2009-03-19 Ludwig Institute Of Cancer Research Method for modifying cellular immune response by modulating activin activity
EP2207562B1 (en) 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
KR20100099193A (ko) 2007-11-21 2010-09-10 암젠 인크 Ｗｉｓｅ 결합 항체 및 에피토프
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
US20110104133A1 (en) 2008-05-06 2011-05-05 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
KR20220002710A (ko) * 2008-06-26 2022-01-06 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
EP2318028B1 (en) 2008-06-26 2020-02-19 Acceleron Pharma Inc. Antagonists of soluble activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PL3494986T3 (pl) 2008-08-14 2020-11-16 Acceleron Pharma Inc. Pułapki GDF
WO2010059861A1 (en) 2008-11-20 2010-05-27 University Of Southern California Compositions and methods to modulate hair growth
CN102245634B (zh) 2008-11-26 2014-10-08 安姆根有限公司 激活素iib受体多肽的变异体及其用途
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
CA2758290C (en) 2009-04-27 2018-04-10 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
KR20200124322A (ko) 2009-08-13 2020-11-02 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
ES2613523T3 (es) 2009-09-09 2017-05-24 Acceleron Pharma, Inc. Antagonistas de ActRIIb y dosificación y usos de los mismos
EP3260130B1 (en) 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US9595813B2 (en) 2011-01-24 2017-03-14 Soraa Laser Diode, Inc. Laser package having multiple emitters configured on a substrate member
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
PL2726099T3 (pl) 2011-07-01 2018-12-31 Novartis Ag Sposób leczenia zaburzeń metabolicznych
BR122019023174B1 (pt) * 2011-10-17 2021-02-23 Acceleron Pharma, Inc Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à esplenomegalia
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
WO2013059876A1 (en) 2011-10-28 2013-05-02 Paranta Biosciences Limited A method of treating mucus hypersecretion
KR20140108562A (ko) 2011-12-19 2014-09-11 암젠 인코퍼레이티드 변이체 액티빈 수용체 폴리펩티드 단독 또는 화학 치료법과의 결합, 및 그들의 용도
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9102212B2 (en) 2012-05-14 2015-08-11 Paccar Inc Fresh air system for heavy duty vehicle cab/sleeper combination
US9663569B2 (en) 2012-06-14 2017-05-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
JP6298762B2 (ja) 2012-07-02 2018-03-20 協和発酵キリン株式会社 抗ｂｍｐ９抗体を有効成分とする、腎性貧血、がん性貧血などの貧血に対する治療剤
HK1214504A1 (zh) 2012-10-24 2016-07-29 细胞基因公司 用於治療貧血的方法
ES2753811T3 (es) 2012-10-24 2020-04-14 Celgene Corp Biomarcador para uso en el tratamiento de anemia
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
EP4566672A3 (en) 2012-11-08 2025-08-13 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
US20150328249A1 (en) 2012-12-11 2015-11-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin strategies and/or ppar gamma ligands, alone or in combination with stem cells, for the therapy of critical limb ischemia and other ischemic processes affecting the skeletal muscle
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
US20160313349A1 (en) 2013-12-16 2016-10-27 Paranta Biosciences Limited Method of diagnosis and treatment
HK1231513A1 (zh) 2014-01-14 2017-12-22 Santa Maria Biotherapeutics, Inc. 活化素抑制劑應答預測和用於治療的用途
US20170248609A1 (en) 2014-01-27 2017-08-31 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
US10260068B2 (en) 2014-03-31 2019-04-16 Sumitomo Dainippon Pharma Co., Ltd. Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
WO2015161220A1 (en) 2014-04-18 2015-10-22 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
WO2015187977A1 (en) 2014-06-04 2015-12-10 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
TN2016000553A1 (en) * 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MX2016016281A (es) 2014-06-13 2017-03-31 Santa Maria Biotherapeutics Inc Polipeptidos receptores formulados y metodos relacionados.
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
US10913782B2 (en) 2015-04-22 2021-02-09 Biogen Ma Inc. Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases
MY189601A (en) * 2015-05-13 2022-02-18 Celgene Corp Treatment of beta-thalassemia using actrii ligand traps
WO2017091706A1 (en) * 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders

Also Published As

Publication number Publication date
AU2021201185A1 (en) 2021-03-11
CA2951926C (en) 2023-01-10
AU2015274277B2 (en) 2021-03-18
JP2020097629A (ja) 2020-06-25
US20220133853A1 (en) 2022-05-05
CN114699529A (zh) 2022-07-05
US20180194834A1 (en) 2018-07-12
WO2015192111A1 (en) 2015-12-17
HK1243640A1 (zh) 2018-07-20
EP3154566A4 (en) 2018-01-24
US20200109193A1 (en) 2020-04-09
MA40008A (fr) 2021-05-05
AU2015274277A1 (en) 2016-12-01
AP2017009674A0 (en) 2017-01-31
CA2951926A1 (en) 2015-12-17
JP2017523140A (ja) 2017-08-17
US10487144B2 (en) 2019-11-26
US9850298B2 (en) 2017-12-26
CN107135646B (zh) 2022-03-15
BR122023023170A2 (pt) 2024-02-20
US20160039922A1 (en) 2016-02-11
TN2016000553A1 (en) 2018-04-04
US11260107B2 (en) 2022-03-01
EP3154566A1 (en) 2017-04-19
MX2021010528A (es) 2021-10-01
JP6669673B2 (ja) 2020-03-18
CN107135646A (zh) 2017-09-05
BR112016029226A2 (pt) 2017-10-17
JP7154243B2 (ja) 2022-10-17
EP3154566B1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
MX2021014748A (es) Kits, dispositivos descartables para reducir el oxigeno y metodos para usarlos.
WO2017096309A8 (en) Methods of treatment of malignancies
EA201791007A2 (ru) Соединения и их применения для модуляции гемоглобина
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
BR112017006664A2 (pt) terapias de combinação
EA201690969A1 (ru) Способы и композиции для лечения связанных со старением состояний
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
PH12017500615A1 (en) Ophthalmic composition comprising cyclosporine and trehalose
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
EA201591399A1 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
PH12019550033A1 (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
WO2017011559A8 (en) Compositions and methods for treating cancer
HK1255053A1 (zh) 用於抑制癌症干细胞的组合物和方法